

**bsm-33061M****[ Primary Antibody ]**

## Cytokeratin 8 Mouse mAb

**Bioss**  
**ANTIBODIES**

www.bioss.com.cn

sales@bioss.com.cn

techsupport@bioss.com.cn

400-901-9800

### — DATASHEET —

**Host:** Mouse**Clonality:** Monoclonal**GeneID:** 3856**Target:** Cytokeratin 8**Purification:** affinity purified by Protein G**Concentration:** 1mg/ml

**Storage:** Size : 50ul/100ul/200ul  
0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.  
Size : 200ug (PBS only)  
0.01M PBS  
Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

**Background:** This gene is a member of the type II keratin family clustered on the long arm of chromosome 12. Type I and type II keratins heteropolymerize to form intermediate-sized filaments in the cytoplasm of epithelial cells. The product of this gene typically dimerizes with keratin 18 to form an intermediate filament in simple single-layered epithelial cells. This protein plays a role in maintaining cellular structural integrity and also functions in signal transduction and cellular differentiation. Mutations in this gene cause cryptogenic cirrhosis. Alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Jan 2012].

Cytokeratin 8 is a member of the type II keratin family clustered on the long arm of chromosome 12. Type I and type II keratins heteropolymerize to form intermediate-sized filaments in the cytoplasm of epithelial cells. Cytokeratin 8 typically dimerizes with keratin 18 to form an intermediate filament in simple single-layered epithelial cells. This protein plays a role in maintaining cellular structural integrity and also functions in signal transduction and cellular differentiation. Mutations in this gene cause cryptogenic cirrhosis.

**Isotype:** IgG**CloneNo.:** 10A8**SWISS:** P05787


**Applications:** IHC-P (1:100-500)  
IHC-F (1:100-500)  
IF (1:200-800)  
Flow-Cyt (1ug/Test)  
ICC/IF (1:100-200)

**Reactivity:** Human, Mouse, Rat


**Predicted**  
**MW.:** 53 kDa

**Subcellular**  
**Location:** Cytoplasm ,Nucleus


### — VALIDATION IMAGES —




Paraformaldehyde-fixed, paraffin embedded (Human colon cancer); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (Cytokeratin 8) Monoclonal Antibody, Unconjugated (bsm-33061M) at 1:400 overnight at 4°C, followed by a conjugated secondary (sp-0023) for 20 minutes and DAB staining.




Paraformaldehyde-fixed, paraffin embedded (mouse liver tissue); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (Cytokeratin 8) Monoclonal Antibody, Unconjugated (bsm-33061M) at 1:400 overnight at 4°C, followed by operating according to SP Kit(Mouse)(sp-0024) instructions and DAB staining.




4% Paraformaldehyde-fixed HeLa (H) cell; Triton X-100 at r.t. for 20 min; Antibody incubation with (Cytokeratin 8) monoclonal Antibody, unconjugated (bsm-33061M) 1:100, 90 min at 37°C; followed by BF488 conjugated Goat Anti-Mouse IgG antibody (green, bs-60296G-BF488) at 37°C for 90 min, DAPI (blue, C02-04002) was used to stain the cell nuclei. PBS instead of the primary antibody was used as the blank control.




Paraformaldehyde-fixed, paraffin embedded (Human cervical cancer); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (Cytokeratin 8) Monoclonal Antibody, Unconjugated (bsm-33061M) at 1:500 overnight at 4°C, followed by a conjugated Goat Anti-Mouse IgG antibody (bs-0296G-CY3) for 90 minutes, and DAPI for nuclei staining.



Paraformaldehyde-fixed, paraffin embedded (Human stomach cancer); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (Cytokeratin 8) Monoclonal Antibody, Unconjugated (bsm-33061M) at 1:500 overnight at 4°C, followed by a conjugated Goat Anti-Mouse IgG antibody (bs-0296G-FITC) for 90 minutes, and DAPI for nuclei staining.



Blank control: MCF-7. Primary Antibody (green line): Mouse Anti-Cytokeratin 8 antibody (bsm-33061M) Dilution: 1ug/Test; Secondary Antibody : Goat anti-mouse IgG-FITC Dilution: 0.5ug/Test. Protocol The cells were fixed with 4% PFA (10min at room temperature)and then permeabilized with 90% ice-cold methanol for 20 min at -20°C.The cells were then incubated in 5%BSA to block non-specific protein-protein interactions for 30 min at room temperature .Cells stained with Primary Antibody for 30 min at room temperature. The secondary antibody used for 40 min at room temperature. Acquisition of 20,000 events was performed.



Blank control: MCF-7. Primary Antibody (green line): Mouse Anti-Cytokeratin 8 antibody (bsm-33061M) Dilution: 1ug/Test; Secondary Antibody : Goat anti-mouse IgG-FITC Dilution: 0.5ug/Test. Protocol The cells were fixed with 4% PFA (10min at room temperature)and then permeabilized with 90% ice-cold methanol for 20 min at -20°C.The cells were then incubated in 5%BSA to block non-specific protein-protein interactions for 30 min at room temperature .Cells stained with Primary Antibody for 30 min at room temperature. The secondary antibody used for 40 min at room temperature. Acquisition of 20,000 events was performed.

## — SELECTED CITATIONS —

- **[IF=7.397]** Takamasa Kido. et al. Effectiveness of interleukin-4 administration or zinc supplementation in improving zinc deficiency-associated thymic atrophy and fatty degeneration and in normalizing T cell maturation process. 2022 Feb 09 IHC ;Rat. 35138640
- **[IF=3.4]** Ziyi Yang. et al. Akkermansia muciniphila enhances the antitumour efficacy of αPD-1 therapy in gastric cancer by remodelling the tumour immune microenvironment. TOXICOL APPL PHARM. 2026 Jan;:117711 IF ;Mouse. 41519274